Oncology and Hematology - MedEd On The Go

Episodes 49-56 of 56

Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
CME/CE
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
0.25 credits
- Heather McArthur, MD
- Margaret Gatti-Mays, MD, MPH
0.25 credits
MinuteCE®
HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI and Platinum-Based Chemotherapy
0.75 credits 6 episodes
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 credits 6 episodes
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
0.75 program credits
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Overcoming EGFR Resistance With HER3-Directed ADCs
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®
Overcoming EGFR Resistance With HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
0.75 program credits
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits

Previous
1
2
3
4
Next

4/4